Cryo-Cell International Q3 Earnings Crush Estimates Despite Flat Revenue

Cryo-Cell International reported a fiscal third-quarter profit that exceeded analyst expectations by a wide margin even as total revenue held virtually flat compared to the same period last year, according to financial figures filed on October 9, 2026. For the quarter ending August 31, 2026, the cord blood and tissue storage specialist posted diluted earnings per share of $0.16, significantly surpassing the consensus estimate of $0.0306.

Key Clinical Takeaways:
• Cryo-Cell International reported fiscal third-quarter earnings per share of $0.16, beating analyst consensus estimates of $0.0306.
• Total quarterly revenue reached $7.82 million, showing a minor 2.9% beat against the $7.60 million consensus but remaining essentially flat compared to $7.83 million in the year-ago period.
• According to SEC filings, recurring storage fee growth was offset by a 15–16% decline in new specimen processing year-to-date.

Divergence Between Earnings and Top-Line Revenue Growth

Total revenue for the quarter reached $7.82 million, edging past the $7.60 million analyst consensus by roughly 2.9% but staying virtually unchanged from the $7.83 million recorded in the corresponding quarter of the previous fiscal year. Net income climbed to $1.27 million, marking an increase of approximately 70% compared to the $749,000 reported during the same period a year earlier.

New Specimen Processing Declines as License Dispute Pauses Initiatives

SEC filings indicate that total revenue was roughly flat year-to-date at about $23.3M versus $23.7M prior-year. However, that recurring growth was directly offset by a 15–16% decline in new specimen processing. Operational capacity has expanded to accommodate third-party biorepository services via a 56,000-square-foot cold storage facility in Durham operating under the ExtraVault brand. Despite these infrastructure investments, broader clinical and biopharmaceutical manufacturing initiatives—alongside the planned Celle spinoff—remain paused due to an ongoing license dispute with Duke University that has put arbitration proceedings on hold.

Analysts Project Revenue Contraction After Company Issues No Guidance

Equity markets exhibited a restrained reaction to the earnings release, with shares moving up 3.47% over the preceding two weeks before dipping fractionally in after-hours trading. Because the company issued no formal revenue or EPS guidance for the fiscal fourth quarter or the full year, sell-side analysts set the remaining baseline expectations. Consensus projections for the fourth quarter anticipate revenue of $7.50 million, representing sequential contraction compared to the $7.82 million just reported. Full-year revenue estimates stand at $30.64 million, translating to anticipated annual growth of roughly 8.2%.